miR-126 作为上皮性卵巢癌预后标志物的临床有效性。

The clinical validity of miR-126 as a prognostic marker in epithelial ovarian cancer.

机构信息

Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

The First College of Clinical Medical Science, China Three Gorges University, Yichang, Hubei, China.

出版信息

Medicine (Baltimore). 2023 Mar 3;102(9):e33085. doi: 10.1097/MD.0000000000033085.

DOI:10.1097/MD.0000000000033085

PMID:36862865

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9981431/

Abstract

BACKGROUND

Ovarian cancer is the leading cause of gynecological cancer related death in females worldwide. Our previous study demonstrated that decreased expression of microRNA (miR-126) promoted ovarian cancer angiogenesis and invasion by targeting VEGF-A. This study aimed to evaluate the clinical validity of miR-126 as a prognostic marker for epithelial ovarian cancer (EOC).

PATIENT CONCERNS

The patients with EOC ranged in age from 27 to 79 years, with a mean age of 57 years.

DIAGNOSIS

All patients had never had chemotherapy or biotherapy, and the diagnoses were confirmed pathologically in all cases.

METHODS

MiR-126 levels in EOC tissue and normal ovaries were determined by qRT-PCR. Its prognostic value was analyzed using the Cox proportional hazards regression model. Survival curves were drawn using the Kaplan-Meier method.

RESULTS

In this study, we found that compared to normal tissues, miR-126 expression was lower in EOC tissues, particularly in omental metastases. Though in our previous study we found that miR-126 may inhibit proliferation and invasion in EOC cell lines, but in this study patients with elevated miR-126 expression exhibited poor overall survival and relapse free survival. Multivariate Cox regression analysis showed that miRNA-126 was an independent prognostic factor for poor relapse-free survival (P = .044). Receiver operating characteristic analysis showed that the area under the curve of miR-126 was 0.806 (95% confidence interval, 0.669-0.942).

CONCLUSION

In this study, we established miR-126 as a potential independent biomarker for predicting recurrence in patients with EOC.

摘要

背景

卵巢癌是全球女性妇科癌症相关死亡的主要原因。我们之前的研究表明，miR-126 表达下调通过靶向 VEGF-A 促进卵巢癌血管生成和侵袭。本研究旨在评估 miR-126 作为上皮性卵巢癌（EOC）预后标志物的临床有效性。

患者关注

EOC 患者年龄 27 岁至 79 岁，平均年龄 57 岁。

诊断

所有患者均未接受过化疗或生物治疗，所有病例均经病理证实诊断。

方法

通过 qRT-PCR 测定 EOC 组织和正常卵巢中的 miR-126 水平。使用 Cox 比例风险回归模型分析其预后价值。使用 Kaplan-Meier 方法绘制生存曲线。

结果

在这项研究中，我们发现与正常组织相比，EOC 组织中 miR-126 的表达较低，尤其是在大网膜转移中。尽管在我们之前的研究中发现 miR-126 可能抑制 EOC 细胞系的增殖和侵袭，但在这项研究中，miR-126 表达升高的患者总体生存和无复发生存较差。多变量 Cox 回归分析显示，miRNA-126 是无复发生存不良的独立预后因素（P=0.044）。受试者工作特征分析显示 miR-126 的曲线下面积为 0.806（95%置信区间，0.669-0.942）。